WHAT THE STUDY ACTUALLY SAYSA six-month randomised trial found liver-fat improvement tracked weight loss and lower ultra-processed food intake, not whether people were assigned a Mediterranean or low-carbohydrate pattern.
4 min read
EXPLAINERHeavy drinking tracks with weight gain fairly consistently. For light-to-moderate drinking, the evidence is genuinely mixed — and confounded by who drinks that way.
3 min read
WHAT THE STUDY ACTUALLY SAYSFeeding studies find that when fructose replaces other carbohydrate at equal calories, liver fat barely moves. The liver damage tracks the extra energy, not the sugar's molecular identity.
4 min read
EXPLAINERA Cochrane review of 18 trials and an NIH-funded randomised trial both failed to show that milk thistle improves liver disease. Product quality is also inconsistent, with some pills contaminated or mislabelled.
4 min read
EXPLAINERNo randomised controlled trial has tested a commercial detox diet in people, and the reviews that exist find no compelling evidence they remove toxins or aid weight. Some carry real risks.
3 min read
EXPLAINERMASLD is excess fat in the liver unrelated to alcohol, and about 30% of adults have it. The best-evidenced way to reverse the inflamed form is weight loss — and how much you lose tracks how much the liver recovers.
3 min read
EXPLAINERRaised liver enzymes are common and mean the liver may be under strain, not that a disease is confirmed. The pattern, degree and duration of the change are what a clinician reads, not a single flag.
4 min read
EXPLAINERThe two dominant causes of chronic liver disease are alcohol and metabolic fat. For alcohol, cirrhosis risk climbs exponentially with intake — and in women it was already raised at about one drink a day.
4 min read
WHAT THE STUDY ACTUALLY SAYSIn moderate-to-heavy drinkers who stopped for a month, insulin resistance fell by a quarter and two cancer-related growth factors dropped sharply — changes a matched control group did not show.
3 min read
WHAT THE STUDY ACTUALLY SAYSEfimosfermin, an FGF21 analogue given every four weeks, was well tolerated over 24 weeks in 84 patients with fatty-liver disease — but this trial was designed to test safety, not whether it heals the liver.
4 min read
This page indexes this newspaper’s reporting on Fatty Liver Disease. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.